Literature DB >> 28974565

Apelin Is a Negative Regulator of Angiotensin II-Mediated Adverse Myocardial Remodeling and Dysfunction.

Zhen-Zhou Zhang1, Wang Wang1, Hai-Yan Jin1, Xueyi Chen1, Yu-Wen Cheng1, Ying-Le Xu1, Bei Song1, Josef M Penninger1, Gavin Y Oudit2, Jiu-Chang Zhong2.   

Abstract

The apelin pathway has emerged as a critical regulator of cardiovascular homeostasis and disease. However, the exact role of pyr1-apelin-13 in angiotensin (Ang) II-mediated heart disease remains unclear. We used apelin-deficient (APLN-/y) and apolipoprotein E knockout mice to evaluate the regulatory roles of pyr1-apelin-13. The 1-year aged APLN-/y mice developed myocardial hypertrophy and dysfunction with reduced angiotensin-converting enzyme 2 levels. Ang II infusion (1.5 mg kg-1 d-1) for 4 weeks potentiated oxidative stress, pathological hypertrophy, and myocardial fibrosis in young APLN-/y hearts resulting in exacerbation of cardiac dysfunction. Importantly, daily administration of 100 μg/kg pyr1-apelin-13 resulted in upregulated angiotensin-converting enzyme 2 levels, decreased superoxide production and expression of hypertrophy- and fibrosis-related genes leading to attenuated myocardial hypertrophy, fibrosis, and dysfunction in the Ang II-infused apolipoprotein E knockout mice. In addition, pyr1-apelin-13 treatment largely attenuated Ang II-induced apoptosis and ultrastructural injury in the apolipoprotein E knockout mice by activating Akt and endothelial nitric oxide synthase phosphorylation signaling. In cultured neonatal rat cardiomyocytes and cardiofibroblasts, exposure of Ang II decreased angiotensin-converting enzyme 2 protein and increased superoxide generation, cellular proliferation, and migration, which were rescued by pyr1-apelin-13, and Akt and endothelial nitric oxide synthase agonist stimulation. The increased superoxide generation and apoptosis in cultured cardiofibroblasts in response to Ang II were strikingly prevented by pyr1-apelin-13 which was partially reversed by cotreatment with the Akt inhibitor MK2206. In conclusion, pyr1-apelin-13 peptide pathway is a negative regulator of aging-mediated and Ang II-mediated adverse myocardial remodeling and dysfunction and represents a potential candidate to prevent and treat heart disease.
© 2017 American Heart Association, Inc.

Entities:  

Keywords:  angiotensin II; dysfunction; hypertension; hypertrophy; oxidative stress

Mesh:

Substances:

Year:  2017        PMID: 28974565     DOI: 10.1161/HYPERTENSIONAHA.117.10156

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  36 in total

1.  Endothelial prolyl hydroxylase 2 is necessary for angiotensin II-mediated renal fibrosis and injury.

Authors:  Yongzhen Zhao; Heng Zeng; Bo Liu; Xiaochen He; Jian-Xiong Chen
Journal:  Am J Physiol Renal Physiol       Date:  2020-07-27

Review 2.  The apelinergic system: a perspective on challenges and opportunities in cardiovascular and metabolic disorders.

Authors:  Eric Marsault; Catherine Llorens-Cortes; Xavier Iturrioz; Hyung J Chun; Olivier Lesur; Gavin Y Oudit; Mannix Auger-Messier
Journal:  Ann N Y Acad Sci       Date:  2019-06-25       Impact factor: 5.691

Review 3.  Leveraging Signaling Pathways to Treat Heart Failure With Reduced Ejection Fraction.

Authors:  Miguel Pinilla-Vera; Virginia S Hahn; David A Kass
Journal:  Circ Res       Date:  2019-05-24       Impact factor: 17.367

Review 4.  Gender Differences in Hypertension.

Authors:  Juan-Juan Song; Zheng Ma; Juan Wang; Lin-Xi Chen; Jiu-Chang Zhong
Journal:  J Cardiovasc Transl Res       Date:  2019-05-01       Impact factor: 4.132

5.  MiRNA-122-5p inhibitor abolishes angiotensin II-mediated loss of autophagy and promotion of apoptosis in rat cardiofibroblasts by modulation of the apelin-AMPK-mTOR signaling.

Authors:  Mei Yang; Juan-Juan Song; Xin-Chun Yang; Guang-Zhen Zhong; Jiu-Chang Zhong
Journal:  In Vitro Cell Dev Biol Anim       Date:  2022-02-07       Impact factor: 2.416

6.  Network Pharmacology and In Vitro Experimental Verification Reveal the Mechanism of the Hirudin in Suppressing Myocardial Hypertrophy.

Authors:  Mengnan Liu; Gang Luo; Li Dong; Maryam Mazhar; Li Wang; Wenlu He; Yan Liu; Qibiao Wu; Hua Zhou; Sijin Yang
Journal:  Front Pharmacol       Date:  2022-06-15       Impact factor: 5.988

7.  ELABELA antagonizes intrarenal renin-angiotensin system to lower blood pressure and protects against renal injury.

Authors:  Chuanming Xu; Fei Wang; Yanting Chen; Shiying Xie; Danielle Sng; Bruno Reversade; Tianxin Yang
Journal:  Am J Physiol Renal Physiol       Date:  2020-03-16

8.  Impact of Apelin-13 on the Development of Coronary Artery Ectasia.

Authors:  Xusen Sun; Yufan Zhang; Xin Qi; Liping Wei
Journal:  Acta Cardiol Sin       Date:  2020-05       Impact factor: 2.672

Review 9.  Cardiac fibrosis.

Authors:  Nikolaos G Frangogiannis
Journal:  Cardiovasc Res       Date:  2021-05-25       Impact factor: 10.787

10.  Sarcolipin haploinsufficiency prevents dystrophic cardiomyopathy in mdx mice.

Authors:  Satvik Mareedu; Ronald Pachon; Jayapalraj Thilagavathi; Nadezhda Fefelova; Rekha Balakrishnan; Nandita Niranjan; Lai-Hua Xie; Gopal J Babu
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-11-20       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.